Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Share-based Compensation (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Share-based Compensation for 11 consecutive years, with $3.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 5.78% to $3.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.8 million through Dec 2025, changed 0.01% year-over-year, with the annual reading at $14.8 million for FY2025, 0.01% changed from the prior year.
  • Share-based Compensation hit $3.5 million in Q4 2025 for Voyager Therapeutics, up from $3.5 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $4.1 million in Q2 2025 to a low of $1.7 million in Q4 2021.
  • Historically, Share-based Compensation has averaged $3.1 million across 5 years, with a median of $3.2 million in 2023.
  • Biggest five-year swings in Share-based Compensation: plummeted 52.77% in 2021 and later soared 51.27% in 2024.
  • Year by year, Share-based Compensation stood at $1.7 million in 2021, then surged by 41.84% to $2.3 million in 2022, then increased by 29.8% to $3.0 million in 2023, then increased by 22.73% to $3.7 million in 2024, then dropped by 5.78% to $3.5 million in 2025.
  • Business Quant data shows Share-based Compensation for VYGR at $3.5 million in Q4 2025, $3.5 million in Q3 2025, and $4.1 million in Q2 2025.